|
1
|
Varo R, Postigo M, Bila R, Dacal E, Chiconela H, García-Villena J, Cuadrado D, Vladimirov A, Díez N, Vallés-López R, Sitoe A, Vitorino P, Mucasse C, Beltran-Agullo L, Pujol O, García V, Abdala M, Sallé L, Anton A, Santos A, Ledesma-Carbayo MJ, Luengo-Oroz M, Bassat Q. Evaluation of the Performance of a 3D-Printed Smartphone-Based Retinal Imaging Device as a Screening Tool for Retinal Pathology in Mozambique. Am J Trop Med Hyg 2023; 109:1192-1198. [PMID: 37918001 PMCID: PMC10622463 DOI: 10.4269/ajtmh.23-0378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Accepted: 08/07/2023] [Indexed: 11/04/2023] Open
Abstract
Low-income countries carry approximately 90% of the global burden of visual impairment, and up to 80% of this could be prevented or cured. However, there are only a few studies on the prevalence of retinal disease in these countries. Easier access to retinal information would allow differential diagnosis and promote strategies to improve eye health, which are currently scarce. This pilot study aims to evaluate the functionality and usability of a tele-retinography system for the detection of retinal pathology, based on a low-cost portable retinal scanner, manufactured with 3D printing and controlled by a mobile phone with an application designed ad hoc. The study was conducted at the Manhiça Rural Hospital in Mozambique. General practitioners, with no specific knowledge of ophthalmology or previous use of retinography, performed digital retinographies on 104 hospitalized patients. The retinographies were acquired in video format, uploaded to a web platform, and reviewed centrally by two ophthalmologists, analyzing the image quality and the presence of retinal lesions. In our sample there was a high proportion of exudates and hemorrhages-8% and 4%, respectively. In addition, the presence of lesions was studied in patients with known underlying risk factors for retinal disease, such as HIV, diabetes, and/or hypertension. Our tele-retinography system based on a smartphone coupled with a simple and low-cost 3D printed device is easy to use by healthcare personnel without specialized ophthalmological knowledge and could be applied for the screening and initial diagnosis of retinal pathology.
Collapse
Affiliation(s)
- Rosauro Varo
- ISGlobal, Hospital Clínic—Universitat de Barcelona, Barcelona, Spain
- Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique
| | | | - Rubao Bila
- Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique
| | | | - Hélio Chiconela
- Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique
| | | | | | | | | | | | - Antonio Sitoe
- Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique
| | - Pio Vitorino
- Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique
| | - Campos Mucasse
- Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique
| | | | - Olivia Pujol
- Institut Català de Retina, Barcelona, Spain
- Hospital Vall d´Hebron, Barcelona, Spain
| | | | - Mariamo Abdala
- Departamento de Oftalmologia, Hospital Central de Maputo, Maputo, Mozambique
- Faculdade de Medicina, Universidade Eduardo Mondlane, Maputo, Mozambique
| | - Lucía Sallé
- Biomedical Image Technologies Group, Departamento de Ingeniería Electrónica, Escuela Técnica Superior de Ingenieros Telecomunicación, Universidad Politécnica de Madrid, Madrid, Spain
| | - Alfonso Anton
- Institut Català de Retina, Barcelona, Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, Madrid, Spain
| | - Andrés Santos
- Biomedical Image Technologies Group, Departamento de Ingeniería Electrónica, Escuela Técnica Superior de Ingenieros Telecomunicación, Universidad Politécnica de Madrid, Madrid, Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, Madrid, Spain
| | - María J. Ledesma-Carbayo
- Biomedical Image Technologies Group, Departamento de Ingeniería Electrónica, Escuela Técnica Superior de Ingenieros Telecomunicación, Universidad Politécnica de Madrid, Madrid, Spain
- CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, Madrid, Spain
| | | | - Quique Bassat
- ISGlobal, Hospital Clínic—Universitat de Barcelona, Barcelona, Spain
- Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique
- Institut Català de Recerca i Estudis Avançats, Barcelona, Spain
- Pediatrics Department, Hospital Sant Joan de Déu, Universitat de Barcelona, Esplugues, Barcelona, Spain
- CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|
|
2
|
Gracia M, Rodríguez E, Diestro MD, Spagnolo E, García V, Siegrist J, Pérez Y, Zapardiel I, Hernández A. Impact of the Covid-19 pandemic on the management of gynecologic cancer: a Spanish survey. Observational, multicenter study. BMC Womens Health 2023; 23:488. [PMID: 37710231 PMCID: PMC10500789 DOI: 10.1186/s12905-023-02633-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Accepted: 09/04/2023] [Indexed: 09/16/2023] Open
Abstract
BACKGROUND The SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) pandemic changed the distribution of healthcare resources, leading in many cases to the suspension of all non-essential treatments and procedures and representing a challenge for medical professionals. The objective of this study was to evaluate whether clinical protocols in gynecologic oncology care were modified as a result of the pandemic and to assess surgeons' perceptions regarding the management of gynecologic cancers". METHODS Data were collected through an anonymous and voluntary survey sent via email to healthcare professionals in the field of gynecologic oncology in Spain. RESULTS A total of 75 gynecologic oncologists completed the online survey. Of these, 93.2% (69) reported working in public hospitals and 62.5% (45) in tertiary care hospitals. 97.3% (71) were affiliated with hospitals treating patients infected with SARS-CoV-2. 85.1% (63) of the respondents expressed concern about the SARS-CoV-2 pandemic and 52.1% (38) indicated that the pandemic impacted the diagnostic and therapeutic quality of care for oncology patients. SARS-CoV-2 nasopharyngeal swab PCR (Polymerase Chain Reaction) testing was always performed before surgical interventions by 97.3% (71), being considered a best practice in triage by 94.4% (68). 87.5% (63) reported no change in the type of surgical approach during the pandemic. 62.5% (45) experienced limitations in accessing special personal protective equipment for SARS-CoV-2. An impact on the follow-up of patients with gynecologic cancers due to the pandemic was reported by 70.4% (50). CONCLUSIONS Most of the Spanish gynecologic oncologists who responded to our survey reported that the SARS-CoV-2 pandemic had affected their clinical practice. The primary measures implemented were an increase in telemedicine, restricting outpatient visits to high-risk or symptomatic patients and the use of SARS-CoV-2 screening prior to surgery. No major changes in the surgical approach or management of the treatment of ovarian, endometrial or cervical cancer during the pandemic were reported.
Collapse
Affiliation(s)
- Myriam Gracia
- Department of Gynecologic Oncology, La Paz University Hospital, Madrid, Spain
| | - Elena Rodríguez
- Department of Gynecology, La Paz University Hospital Hospital Universitario La Paz, Madrid, Spain, 28046, Paseo de la Castellana, 261
| | | | - Emanuela Spagnolo
- Department of Gynecology, La Paz University Hospital Hospital Universitario La Paz, Madrid, Spain, 28046, Paseo de la Castellana, 261.
| | - Virginia García
- Department of Gynecologic Oncology, La Paz University Hospital, Madrid, Spain
| | - Jaime Siegrist
- Department of Gynecologic Oncology, La Paz University Hospital, Madrid, Spain
| | - Yolanda Pérez
- Department of Gynecologic Oncology, La Paz University Hospital, Madrid, Spain
| | - Ignacio Zapardiel
- Department of Gynecologic Oncology, La Paz University Hospital, Madrid, Spain
| | - Alicia Hernández
- Department of Gynecologic Oncology, La Paz University Hospital, Madrid, Spain
| |
Collapse
|
|
3
|
San Martín-López JV, Mesa N, Bernal-Bello D, Morales-Ortega A, Rivilla M, Guerrero M, Calderón R, Farfán AI, Rivas L, Soria G, Izquierdo A, Madroñal E, Duarte M, Piedrabuena S, Toledano-Macías M, Marrero J, de Ancos C, Frutos B, Cristóbal R, Velázquez L, Mora B, Cuenca P, Satué JÁ, Ayala-Larrañaga I, Carpintero L, Lara C, Llerena ÁR, García V, García de Viedma V, Prieto S, González-Pereira N, Bravo C, Mariño C, Lechuga LA, Tarancón J, Gonzalo S, Moreno S, Ruiz-Giardin JM. Seven Epidemic Waves of COVID-19 in a Hospital in Madrid: Analysis of Severity and Associated Factors. Viruses 2023; 15:1839. [PMID: 37766248 PMCID: PMC10538062 DOI: 10.3390/v15091839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Revised: 08/21/2023] [Accepted: 08/28/2023] [Indexed: 09/29/2023] Open
Abstract
(1) Background: COVID-19 has evolved during seven epidemic waves in Spain. Our objective was to describe changes in mortality and severity in our hospitalized patients. (2) Method: This study employed a descriptive, retrospective approach for COVID-19 patients admitted to the Hospital de Fuenlabrada (Madrid, Spain) until 31 December 2022. (3) Results: A total of 5510 admissions for COVID-19 were recorded. The first wave accounted for 1823 (33%) admissions and exhibited the highest proportion of severe patients: 65% with bilateral pneumonia and 83% with oxygen saturation under 94% during admission and elevated levels of CRP, IL-6, and D-dimer. In contrast, the seventh wave had the highest median age (79 years) and comorbidity (Charlson: 2.7), while only 3% of patients had bilateral pneumonia and 3% required intubation. The overall mortality rate was 10.3%. The first wave represented 39% of the total. The variables related to mortality were age (OR: 1.08, 1.07-1.09), cancer (OR: 1.99, 1.53-2.60), dementia (OR: 1.82, 1.20-2.75), the Charlson index (1.38, 1.31-1.47), the need for high-flow oxygen (OR: 6.10, 4.94-7.52), mechanical ventilation (OR: 11.554, 6.996-19.080), and CRP (OR: 1.04, 1.03-1.06). (4) Conclusions: The variables associated with mortality included age, comorbidity, respiratory failure, and inflammation. Differences in the baseline characteristics of admitted patients explained the differences in mortality in each wave. Differences observed between patients admitted in the latest wave and the earlier ones suggest that COVID-19 has evolved into a distinct disease, requiring a distinct approach.
Collapse
Affiliation(s)
- Juan Víctor San Martín-López
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
- CIBERINFEC, Instituto de Salud Carlos III, Madrid, 28029 Madrid, Spain;
| | - Nieves Mesa
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - David Bernal-Bello
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Alejandro Morales-Ortega
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
- Departamento de Medicina y Especialidades Médicas, Universidad de Alcalá, 28871 Madrid, Spain
| | - Marta Rivilla
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Marta Guerrero
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Ruth Calderón
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Ana I. Farfán
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Luis Rivas
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Guillermo Soria
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Aída Izquierdo
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Elena Madroñal
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Miguel Duarte
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Sara Piedrabuena
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - María Toledano-Macías
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Jorge Marrero
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Cristina de Ancos
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Begoña Frutos
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Rafael Cristóbal
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Laura Velázquez
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Belén Mora
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Paula Cuenca
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - José Á. Satué
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Ibone Ayala-Larrañaga
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Lorena Carpintero
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Celia Lara
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Álvaro R. Llerena
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Virginia García
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Vanessa García de Viedma
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Santiago Prieto
- Servicio de Laboratorio Clínico, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (S.P.); (N.G.-P.)
| | - Natalia González-Pereira
- Servicio de Laboratorio Clínico, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (S.P.); (N.G.-P.)
| | - Cristina Bravo
- Servicio de Farmacia, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (C.B.); (C.M.)
| | - Carolina Mariño
- Servicio de Farmacia, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (C.B.); (C.M.)
| | - Luis Antonio Lechuga
- Sistemas, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (L.A.L.); (J.T.)
| | - Jorge Tarancón
- Sistemas, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (L.A.L.); (J.T.)
| | - Sonia Gonzalo
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
| | - Santiago Moreno
- CIBERINFEC, Instituto de Salud Carlos III, Madrid, 28029 Madrid, Spain;
- Departamento de Medicina y Especialidades Médicas, Universidad de Alcalá, 28871 Madrid, Spain
- Servicio de Enfermedades Infecciosas, Hospital U. Ramón y Cajal, IRYCIS, 28034 Madrid, Spain
| | - José M. Ruiz-Giardin
- Servicio de Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain; (N.M.); (D.B.-B.); (A.M.-O.); (M.R.); (M.G.); (R.C.); (A.I.F.); (L.R.); (G.S.); (A.I.); (E.M.); (M.D.); (S.P.); (M.T.-M.); (J.M.); (C.d.A.); (B.F.); (R.C.); (L.V.); (B.M.); (P.C.); (J.Á.S.); (I.A.-L.); (L.C.); (C.L.); (Á.R.L.); (V.G.); (V.G.d.V.); (S.G.); (J.M.R.-G.)
- CIBERINFEC, Instituto de Salud Carlos III, Madrid, 28029 Madrid, Spain;
| |
Collapse
|
|
4
|
García E, Paredes V, Bellot C, García V, Aura JI, Borrell C, Dioguardi M, Garcovich D, Aiuto R, Marqués L. Bibliometric analysis in paediatric dental journals listed in journal citation reports. Current trends. EUROPEAN JOURNAL OF PAEDIATRIC DENTISTRY 2022; 23:262-268. [PMID: 36511915 DOI: 10.23804/ejpd.2022.23.04.02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
AIM The aim of this study was to analyse articles published in paediatric dental journals included in Journal Citation Reports (JCR), to determine current trends in paediatric publishing. METHODS Articles included in paediatric dentistry journals in 2020 JCR were selected, published during the period 2008-2020. After applying inclusion criteria, author-based parameters (article title, first author's name, institution, sex and number of authors, number of affiliations, first/last author's origin and geographic origin), and article-based parameters (article type, main topic, research design) were registered for each article. CONCLUSION International Journal of Paediatric Dentistry, Journal of Clinical Pediatric Dentistry, European Journal of Paediatric Dentistry and Pediatric Dentistry were the four main journals in terms of production volume, USA being the most productive country. The most recurrent topic was dental surgery, and the most common design was observational studies. Study design, geographic origin of the articles, article type and main subject of the article might predict citation.
Collapse
Affiliation(s)
- E García
- Faculty of Medicine and Health Sciences, Catholic University of Valencia, Valencia, Spain
| | - V Paredes
- Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain
| | - C Bellot
- Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain
| | - V García
- Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain
| | - J I Aura
- Faculty of Medicine and Health Sciences, Catholic University of Valencia, Valencia, Spain
| | - C Borrell
- Faculty of Medicine and Health Sciences, Catholic University of Valencia, Valencia, Spain
| | - M Dioguardi
- Department of Clinical and Experimental Medicine, University of Foggia, Italy
| | - D Garcovich
- Master in Orthodontics, Universidad Europea de Valencia, Valencia, Spain
| | - R Aiuto
- Department of Biomedical, Surgical and Dental Sciences, University of Milan - Istituto Stomatologico Italiano, Milan, Italy
| | - L Marqués
- Faculty of Medicine and Health Sciences, Catholic University of Valencia, Valencia, Spain
| |
Collapse
|
|
5
|
Ruiz-Giardin JM, Rivilla M, Mesa N, Morales A, Rivas L, Izquierdo A, Escribá A, San Martín JV, Bernal-Bello D, Madroñal E, Farfán AI, Guerrero M, Calderón R, Duarte MA, Piedrabuena SI, Toledano-Macías M, Satué JÁ, Marrero J, de Ancos CL, Frutos B, Cristóbal R, Soria G, Ayala-Larrañaga I, Carpintero L, de Hita M, Lara C, Llerena ÁR, García V, Jiménez R, García V, Saiz-Lou EM, Prieto S, González-Pereira N, Lechuga LA, Tarancón J, Gonzalo S. Comparative Study of Vaccinated and Unvaccinated Hospitalised Patients: A Retrospective Population Study of 500 Hospitalised Patients with SARS-CoV-2 Infection in a Spanish Population of 220,000 Inhabitants. Viruses 2022; 14:v14102284. [PMID: 36298839 PMCID: PMC9611498 DOI: 10.3390/v14102284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Revised: 10/12/2022] [Accepted: 10/13/2022] [Indexed: 11/23/2022] Open
Abstract
Objectives. This study aimed to compare the characteristics of fully and partially vaccinated or unvaccinated coronavirus disease 2019 (COVID-19) patients who were hospitalised in a population of 220,000 habitants. Methods: Retrospective, observational, and population studies were conducted on patients who were hospitalised due to COVID-19 from March to October 2021. We assessed the impact of vaccination and other risk factors through Cox multivariate analysis. Results: A total of 500 patients were hospitalised, among whom 77 (15.4%) were fully vaccinated, 86 (17.2%) were partially vaccinated, and 337 (67.4%) were unvaccinated. Fully vaccinated (FV) patients were older and had a higher Charlson index than those of partially vaccinated and unvaccinated patients (NFV). Bilateral pneumonia was more frequent among NFV (259/376 (68.9%)) than among FV patients (32/75 (42.7%)). The former had more intensive care unit admissions (63/423) than the latter (4/77); OR: 2.80; CI (1.07–9.47). Increasing age HZ: 1.1 (1.06–1.14)) and haematological disease at admission HZ: 2.99 (1.26–7.11)) were independent risk factors for higher mortality during the first 30 days of hospitalisation. The probability of an earlier discharge in the subgroup of 440 patients who did not die during the first 30 days of hospitalisation was related to age (older to younger: HZ: 0.98 (0.97–0.99)) and vaccination status. Conclusions: Among the patients hospitalised because of COVID-19, complete vaccination was associated with less severe forms of COVID-19, with an earlier discharge date. Age and haematological disease were related to a higher mortality rate during the first 30 days of hospitalisation.
Collapse
Affiliation(s)
- José M. Ruiz-Giardin
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
- CIBERINFEC, 28029 Madrid, Spain
- Correspondence: ; Tel.: +34-916006179
| | - Marta Rivilla
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Nieves Mesa
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Alejandro Morales
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Luis Rivas
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Aída Izquierdo
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Almudena Escribá
- Oficina Regional de Coordinación de Transplante de la Comunidad de Madrid, 28046 Madrid, Spain
| | - Juan V. San Martín
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
- CIBERINFEC, 28029 Madrid, Spain
| | - David Bernal-Bello
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Elena Madroñal
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Ana I. Farfán
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Marta Guerrero
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Ruth Calderón
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Miguel A. Duarte
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Sara I. Piedrabuena
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | | | - José Á. Satué
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Jorge Marrero
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | | | - Begoña Frutos
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Rafael Cristóbal
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Guillermo Soria
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | | | - Lorena Carpintero
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Miguel de Hita
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Celia Lara
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Álvaro R. Llerena
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Virginia García
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Raquel Jiménez
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Vanesa García
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Elena M. Saiz-Lou
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Santiago Prieto
- Laboratorio Clínico, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | | | | | - Jorge Tarancón
- Sistemas, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| | - Sonia Gonzalo
- Medicina Interna, Hospital Universitario de Fuenlabrada, 28942 Madrid, Spain
| |
Collapse
|
|
6
|
Castillo L, Berrozpe‐Villabona C, Miserachs‐García S, Haulani H, Gómez‐Gutiérrez C, Díaz‐García RS, González‐Martínez A, Fernández‐Sanz G, Morilla‐Grasa A, García V, Arias L, Caminal JM, Casaroli‐Marano R. Quantitative assessment of macular and circumpapillary retinal vessel density across all stages of Leber hereditary optic neuropathy using swept source optical coherence tomography angiography. Acta Ophthalmol 2022; 100:e1646-e1656. [PMID: 35524395 DOI: 10.1111/aos.15169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2021] [Accepted: 04/19/2022] [Indexed: 11/30/2022]
Abstract
PURPOSE To investigate the macular and circumpapillary retinal microvasculature across all stages of Leber hereditary optic neuropathy (LHON) using swept source optical coherence tomography angiography (OCTA). METHODS This prospective, multicentre, cross-sectional, observational study analysed a total of 119 eyes of 60 patients with molecularly confirmed LHON across all stages and 120 eyes of 60 control subjects. Optical coherence tomography angiography maps centred on the fovea and optic disc were obtained to measure vessel densities (VDs) in the macular superficial (SCP) and deep (DCP) capillary plexuses, and the radial peripapillary capillary plexus (RPCP) respectively. RESULTS In asymptomatic eyes, only the SCP showed significant changes on average (B coefficient = -0.72, 95% CI = -1.34 to -0.10, p = 0.022) or in sectors representing the papillomacular bundle (PMB) (B coefficient = -1.17, 95% CI = -2.23 to -0.11, p = 0.031). However, in chronic eyes, the greatest magnitude of change was found in the temporal sector of the RPCP (B coefficient = -12.36, 95% CI = -14.49 to -10.23, p < 0.001). The RPCP showed the strongest correlations with visual acuity (VA, logarithm of the minimum angle of resolution; R = -0.677, p < 0.001) and structural parameters (R = 0.747, p < 0.001). CONCLUSIONS Retinal VD changes in the circumpapillary region of the PMB appear later than in the macula but end up being more profound and correlate better with VA and structural parameters. Further studies are needed to assess the clinical utility of retinal VDs as potential LHON biomarkers.
Collapse
Affiliation(s)
| | - Clara Berrozpe‐Villabona
- Department of Ophthalmology University Clinic of Navarra Madrid Spain
- Department of Ophthalmology University Clinic of Navarra Pamplona Spain
- Thematic Network of Cooperative Health Research in Eye Diseases (Oftared) Health Institute Carlos III Madrid Spain
| | - Sergio Miserachs‐García
- Clinical Institute of Ophthalmology (ICOF) – Plató Centre Clinic Hospital of Barcelona Barcelona Spain
| | | | | | | | | | - Guillermo Fernández‐Sanz
- Department of Ophthalmology University Clinic of Navarra Madrid Spain
- Thematic Network of Cooperative Health Research in Eye Diseases (Oftared) Health Institute Carlos III Madrid Spain
| | | | | | - Luis Arias
- Department of Ophthalmology Bellvitge University Hospital, L'Hospitalet de Llobregat Barcelona Spain
- Bellvitge Biomedical Research Institute (IDIBELL) L'Hospitalet de Llobregat Barcelona Spain
| | - José M. Caminal
- Department of Ophthalmology Bellvitge University Hospital, L'Hospitalet de Llobregat Barcelona Spain
- Bellvitge Biomedical Research Institute (IDIBELL) L'Hospitalet de Llobregat Barcelona Spain
| | - Ricardo Casaroli‐Marano
- Department of Surgery School of Medicine and Health Sciences Clinic Hospital of Barcelona University of Barcelona Barcelona Spain
| |
Collapse
|
|
7
|
Jiménez-Romero C, Justo I, Marcacuzco A, García V, Manrique A, García-Sesma Á, Calvo J, Caso Ó, Fernández I. Authors' response to Cai et al. on their commentary on "Safe use of livers from deceased donors older than 70 years in recipients with HCV cirrhosis treated with direct-action antivirals" (Int J Surg 2021, 106096). Int J Surg 2021; 95:106146. [PMID: 34688929 DOI: 10.1016/j.ijsu.2021.106146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2021] [Accepted: 10/15/2021] [Indexed: 11/29/2022]
Affiliation(s)
- Carlos Jiménez-Romero
- Unit of HPB Surgery and Abdominal Organ Transplantation, "Doce de Octubre" Hospital, Spain Service of Gastroenterology, Instituto de Investigación (imas12), Department of Surgery, Faculty of Medicine, Complutense University, Madrid, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
|
8
|
Almén A, Andersson M, O’Connor U, Abdelrahman M, Camp A, García V, Duch MA, Ginjaume M, Vanhavere F. PERSONAL DOSIMETRY USING MONTE-CARLO SIMULATIONS FOR OCCUPATIONAL DOSE MONITORING IN INTERVENTIONAL RADIOLOGY: THE RESULTS OF A PROOF OF CONCEPT IN A CLINICAL SETTING. Radiat Prot Dosimetry 2021; 195:391-398. [PMID: 33823548 PMCID: PMC8507461 DOI: 10.1093/rpd/ncab045] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 02/09/2021] [Accepted: 03/05/2021] [Indexed: 06/12/2023]
Abstract
Exposure levels to staff in interventional radiology (IR) may be significant and appropriate assessment of radiation doses is needed. Issues regarding measurements using physical dosemeters in the clinical environment still exist. The objective of this work was to explore the prerequisites for assessing staff radiation dose, based on simulations only. Personal dose equivalent, Hp(10), was assessed using simulations based on Monte Carlo methods. The position of the operator was defined using a 3D motion tracking system. X-ray system exposure parameters were extracted from the x-ray equipment. The methodology was investigated and the simulations compared to measurements during IR procedures. The results indicate that the differences between simulated and measured staff radiation doses, in terms of the personal dose equivalent quantity Hp(10), are in the order of 30-70 %. The results are promising but some issues remain to be solved, e.g. an automated tracking of movable parts such as the ceiling-mounted protection shield.
Collapse
Affiliation(s)
- A Almén
- Medical Radiation Physics, Department of Translational Medicine, Lund University, Malmö, Sweden
- Department of Radiation Protection, Swedish Radiation Safety Authority, Stockholm, Sweden
| | - M Andersson
- Medical Radiation Physics, Department of Translational Medicine, Lund University, Malmö, Sweden
| | - U O’Connor
- Department of Medical Physics and Bioengineering, St James’s Hospital, Dublin, Ireland
| | - M Abdelrahman
- The Belgian Nuclear Research Center, Boeretang, Belgium
| | - A Camp
- Institut de Tècniques Energètiques, Universitat Politècnica de Catalunya (UPC), Barcelona, Spain
| | - V García
- Institut de Tècniques Energètiques, Universitat Politècnica de Catalunya (UPC), Barcelona, Spain
| | - M A Duch
- Institut de Tècniques Energètiques, Universitat Politècnica de Catalunya (UPC), Barcelona, Spain
| | - M Ginjaume
- Institut de Tècniques Energètiques, Universitat Politècnica de Catalunya (UPC), Barcelona, Spain
| | - F Vanhavere
- The Belgian Nuclear Research Center, Boeretang, Belgium
| |
Collapse
|
|
9
|
Seitz J, Vicharelli G, García V, Vissio C, Estanguet A, Parada J, Carranza A, Di Cola G, Tamiozzo P. Ureaplasma diversum and Ureaplasma sp. in nasal cavity of pigs: Distribution among herds and individual frequency based on pooled samples. Rev Argent Microbiol 2020; 53:141-144. [PMID: 33386175 DOI: 10.1016/j.ram.2020.11.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2019] [Revised: 09/12/2020] [Accepted: 11/09/2020] [Indexed: 11/19/2022] Open
Abstract
The role of Ureaplasma diversum in the porcine respiratory disease complex (PRDC), its circulation among herds and prevalence in live pigs is unknown; thus, the objectives of this study were: to determine the presence of U. diversum in indoor intensive pig herds and to determine the individual frequency of pigs with U. diversum from pooled samples. A cross sectional study was carried out in 16 indoor intensive herds from Córdoba and La Pampa provinces, collecting eight nasal swabs specimens that were further processed by two pools of four specimens each by a PCR targeting a fragment of 16S ribosomal RNA gene. Four PCR products were sequenced and aligned against data bases. U. diversum - Ureaplasma sp. were detected in 56.3% of the analyzed herds, with 16.5% (95% CI 8.2-30.8) of positive pigs. It was concluded that U. diversum - Ureaplasma sp. are present in the nasal cavity of live pigs, being widely distributed among herds.
Collapse
Affiliation(s)
- Jimena Seitz
- Department of Animal Pathology, Faculty of Agronomy and Veterinary, National University of Río Cuarto, Córdoba, Argentina
| | - Gastón Vicharelli
- Department of Animal Pathology, Faculty of Agronomy and Veterinary, National University of Río Cuarto, Córdoba, Argentina
| | - Virginia García
- Department of Animal Pathology, Faculty of Agronomy and Veterinary, National University of Río Cuarto, Córdoba, Argentina
| | - Claudina Vissio
- Department of Animal Pathology, Faculty of Agronomy and Veterinary, National University of Río Cuarto, Córdoba, Argentina; CONICET, Argentina
| | - Abel Estanguet
- Department of Animal Pathology, Faculty of Agronomy and Veterinary, National University of Río Cuarto, Córdoba, Argentina
| | - Julián Parada
- Department of Animal Pathology, Faculty of Agronomy and Veterinary, National University of Río Cuarto, Córdoba, Argentina; CONICET, Argentina
| | - Alicia Carranza
- Department of Animal Pathology, Faculty of Agronomy and Veterinary, National University of Río Cuarto, Córdoba, Argentina
| | - Gabriel Di Cola
- Department of Animal Pathology, Faculty of Agronomy and Veterinary, National University of Río Cuarto, Córdoba, Argentina
| | - Pablo Tamiozzo
- Department of Animal Pathology, Faculty of Agronomy and Veterinary, National University of Río Cuarto, Córdoba, Argentina.
| |
Collapse
|
|
10
|
Cambra MJ, Moreno F, Sanz X, Anglada L, Mollà M, Reyes V, Arenas M, Pedro A, Ballester R, García V, Casals J, Cusidó M, Jimenez C, Escribà JM, Macià M, Solé JM, Arcusa A, Seguí MA, Gonzalez S, Farrús B, Biete A. Role of boost radiotherapy for local control of pure ductal carcinoma in situ after breast-conserving surgery: a multicenter, retrospective study of 622 patients. Clin Transl Oncol 2019; 22:670-680. [PMID: 31264148 DOI: 10.1007/s12094-019-02168-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2018] [Accepted: 06/19/2019] [Indexed: 12/01/2022]
Abstract
PURPOSE To evaluate the effect of boost radiotherapy on ipsilateral breast tumor recurrence (IBTR) for ductal carcinoma in situ (DCIS) after breast-conserving surgery and whole breast radiotherapy (WBRT) with or without boost. METHODS AND MATERIALS Retrospective, multicentre study of 622 patients (624 tumors) diagnosed with pure DCIS from 1993-2011. RESULTS Most tumors (377/624; 60.4%) received a boost. At a median follow-up of 8.8 years, IBTR occurred in 64 cases (10.3%). A higher percentage of patients with risk factors for IBTR received a boost (p < 0.05). Boost was not associated with lower rates of IBTR than WBRT alone (HR 0.75, 95% CI 0.42-1.35). On the univariate analyses, IBTR was significantly associated with tumor size (11-20 mm, HR 2.32, 95% CI 1.27-4.24; and > 20 mm, HR 2.10, 95% CI 1.14-3.88), re-excision (HR 1.76, 95% CI 1.04-2.96), and tamoxifen (HR 2.03, 95% CI 1.12-3.70). Boost dose > 16 Gy had a protective effect (HR 0.39, 95% CI 0.187-0.824). Multivariate analyses confirmed the independent associations between IBTR and 11-20 mm (p = 0.02) and > 20 mm (p = 0.009) tumours, and re-excision (p = 0.006). On the margin-stratified multivariate analysis, tamoxifen was a poor prognostic factor in the close/positive margin subgroup (HR 4.28 95% CI 1.23-14.88), while the highest boost dose ( > 16 Gy) had a significant positive effect (HR 0.34, 95% CI 0.13-0.86) in the negative margin subgroup. CONCLUSIONS Radiotherapy boost did not improve the risk of IBTR. Boost radiotherapy was more common in patients with high-risk disease. Tumor size and re-excision were significant independent prognostic factors.
Collapse
Affiliation(s)
- M J Cambra
- Department of Radiation Oncology, Hospital Universitari General de Catalunya-Grupo Quirónsalud (IOV-HGC-Quironsalud), Carrer Pedro i Pons 1, 08195, Sant Cugat del Vallés, Barcelona, Spain.
| | - F Moreno
- Department of Radiation Oncology, Institut Català d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Avda de la Granvia, 199, 08908, Barcelona, Spain
| | - X Sanz
- Department of Radiation Oncology, Parc de Salut MAR, Passeig Marítim 25-29, 08003, Barcelona, Spain
| | - L Anglada
- Department of Radiation Oncology, ICO Girona, Avda de França, s/n, 17007, Girona, Spain
| | - M Mollà
- Department of Radiation Oncology, Hospital Vall d'Hebrón, Pg Vall d'Hebron 119, 129, 08035, Barcelona, Spain.,Department of Radiation Oncology, Hospital Clìnic, Universitat de Barcelona, Villarroel 170, 08036, Barcelona, Spain
| | - V Reyes
- Department of Radiation Oncology, Hospital Vall d'Hebrón, Pg Vall d'Hebron 119, 129, 08035, Barcelona, Spain
| | - M Arenas
- Department of Radiation Oncology, Hospital Universitari Sant Joan Reus, Avda del Dr. Josep Laporte, 2, 43204, Reus, Tarragona, Spain
| | - A Pedro
- Department of Radiation Oncology, Hospital Plató, c/Plató, 21, 08006, Barcelona, Spain
| | - R Ballester
- Department of Radiation Oncology, Institut Català D'Oncologia-Badalona, Carretera del Canyet, s/n, 08916, Badalona, Barcelona, Spain
| | - V García
- Department of Radiation Oncology, Hospital Arnau de Vilanova, Avda Alcalde Rovira Roure, 80, 25198, Lleida, Spain
| | - J Casals
- Department of Radiation Oncology, Hospital Quirón, Plaça Alfonso Comín, 5, 08023, Barcelona, Spain
| | - M Cusidó
- Department of Gynecology and Obstetrics, Hospital Universitari Dexeus-Grupo Quirónsalud, c/Sabino Arana, 5-19, 08028, Barcelona, Spain
| | - C Jimenez
- Biostatistics and Bioinformatic Expert, Olesa de Montserrat, c/Urgell 55 A, 08640, Barcelona, Spain
| | - J M Escribà
- Catalan Cancer Registry, Cancer Planning Directorate, L'Hospitalet de Llobregat, Avda de La Granvia, s/n, 08908, Barcelona, Spain.,Department of Clinical Sciences, University of Barcelona, Barcelona, Spain
| | - M Macià
- Department of Radiation Oncology, Institut Català d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Avda de la Granvia, 199, 08908, Barcelona, Spain
| | - J M Solé
- Department of Radiation Oncology, Consorci Sanitari de Terrassa, Ctra. Torrebonica s/n, 08227, Terrassa, Barcelona, Spain
| | - A Arcusa
- Department of Medical Oncology, Ctra. Torrebonica s/n, Consorci Sanitari de Terrassa, 08227, Terrassa, Barcelona, Spain
| | - M A Seguí
- Department of Medical Oncology, Corporació Sanitaria Parc Taulí, Parc Taulí 1, 08208, Sabadell, Barcelona, Spain
| | - S Gonzalez
- Department of Medical Oncology, Hospital Universitari Mútua de Terrassa, Plaça del Doctor Robert, 5, 08221, Terrassa, Barcelona, Spain
| | - B Farrús
- Department of Radiation Oncology, Hospital Clìnic, Universitat de Barcelona, Villarroel 170, 08036, Barcelona, Spain
| | - A Biete
- Department of Radiation Oncology, Hospital Clìnic, Universitat de Barcelona, Villarroel 170, 08036, Barcelona, Spain
| |
Collapse
|
|
11
|
|
|
12
|
Bonet M, Arenas M, Farré N, García V, Algara M, Farrús B, Fernández J, Reyes V, Eraso A, Alvarez A, Cambra M, Pedro A, Vayreda J, Montero A, Poortmans P. EP-1297: RT for bone-only oligometastases in breast cancer patients: a survey of current clinical practice. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31607-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
|
13
|
Cambra M, Farrús B, Moreno F, Anglada L, Arenas M, Ballester R, Casals J, Cusidó M, García V, Gutiérrez C, Mollà M, Pedro A, Reyes V, Sanz X. Management of breast ductal carcinoma in situ in Catalonia, Spain: Results from the Grup Oncologic Calalà-Occità-Catalonia survey with 9-year follow up. Breast 2017; 35:196-202. [DOI: 10.1016/j.breast.2017.08.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2017] [Revised: 07/31/2017] [Accepted: 08/07/2017] [Indexed: 12/25/2022] Open
|
|
14
|
Yeramian A, García V, Bergadà L, Domingo M, Santacana M, Valls J, Martinez-Alonso M, Carceller JA, Cussac AL, Dolcet X, Matias-Guiu X. Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer. Mol Imaging Biol 2017; 18:545-56. [PMID: 26604096 DOI: 10.1007/s11307-015-0907-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
PURPOSE In this study, we first aimed to evaluate the effects in vitro and in vivo, of the Hsp90 inhibitor NVP-AUY922, in endometrial cancer (EC). We also aimed to track nuclear factor kappa B (NF-κB) signalling, a key pathway involved in endometrial carcinogenesis and to check whether NVP-AUY922 treatment modulates it both in vitro and in vivo. PROCEDURES I n vitro effects of NVP-AUY922 on EC cell growth and the signalling pathways were assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), clonogenic assays, Western Blot and luciferase assay. NVP-AUY922 effect on Ishikawa (IK) xenograft growth was evaluated in vivo, and NF-κB activity was monitored using bioluminescence imaging. RESULTS NVP-AUY922 inhibited the growth of three endometrial cell lines tested in vitro. In vivo, NVP-AUY922 reduced tumour growth of 47 % (p = 0.042) compared to control condition. Moreover, the bioluminescence signal of the tumours harbouring IK NF-κB-LUC cells was significantly reduced in NVP-AUY922-treated animals compared to untreated ones. CONCLUSIONS NVP-AUY922 reduced EC tumour growth and NF-κB signalling both in vitro and in vivo. As therapeutic resistance of EC remains a challenge for oncologists nowadays, we think that NVP-AUY922 represents a valid alternative to conventional chemotherapy, and we believe that this approach for assessing and tracking the activation of NF-κB pathway may be of therapeutic benefit.
Collapse
Affiliation(s)
- Andree Yeramian
- Department of Pathology and Molecular Genetics HUAV, Dept de Ciències Mèdiques Bàsiques, Institut de Recerca Biomedica de Lleida, Univeristy of Lleida, IRBLleida, Avenida Rovira Roure, No. 80, 25198, Lleida, Spain.
| | - Virginia García
- Department of Radiation Oncology, Hospital Universitari Arnau de Vilanova, Avenida Rovira Roure, No. 80, 25198, Lleida, Spain
| | - Laura Bergadà
- Department of Pathology and Molecular Genetics HUAV, Dept de Ciències Mèdiques Bàsiques, Institut de Recerca Biomedica de Lleida, Univeristy of Lleida, IRBLleida, Avenida Rovira Roure, No. 80, 25198, Lleida, Spain
| | - Mónica Domingo
- Department of Pathology and Molecular Genetics HUAV, Dept de Ciències Mèdiques Bàsiques, Institut de Recerca Biomedica de Lleida, Univeristy of Lleida, IRBLleida, Avenida Rovira Roure, No. 80, 25198, Lleida, Spain
| | - Maria Santacana
- Department of Pathology and Molecular Genetics HUAV, Dept de Ciències Mèdiques Bàsiques, Institut de Recerca Biomedica de Lleida, Univeristy of Lleida, IRBLleida, Avenida Rovira Roure, No. 80, 25198, Lleida, Spain
| | - Joan Valls
- Biostatistics Unit, Hospital Universitari Arnau de Vilanova, University of Lleida, IRB-Lleida, Avenida Rovira Roure, No. 80, 25198, Lleida, Spain
| | - Montserrat Martinez-Alonso
- Biostatistics Unit, Hospital Universitari Arnau de Vilanova, University of Lleida, IRB-Lleida, Avenida Rovira Roure, No. 80, 25198, Lleida, Spain
| | - José-Antonio Carceller
- Department of Radiation Oncology, Hospital Universitari Arnau de Vilanova, Avenida Rovira Roure, No. 80, 25198, Lleida, Spain
| | - Antonio Llombart Cussac
- Department of Oncology, Hospital Universitari Arnau de Vilanova, University of Lleida, IRB-Lleida, Avenida Rovira Roure, No. 80, 25198, Lleida, Spain
| | - Xavier Dolcet
- Department of Pathology and Molecular Genetics HUAV, Dept de Ciències Mèdiques Bàsiques, Institut de Recerca Biomedica de Lleida, Univeristy of Lleida, IRBLleida, Avenida Rovira Roure, No. 80, 25198, Lleida, Spain
| | - Xavier Matias-Guiu
- Department of Pathology and Molecular Genetics HUAV, Dept de Ciències Mèdiques Bàsiques, Institut de Recerca Biomedica de Lleida, Univeristy of Lleida, IRBLleida, Avenida Rovira Roure, No. 80, 25198, Lleida, Spain
| |
Collapse
|
|
15
|
León VM, Moreno-González R, García V, Campillo JA. Impact of flash flood events on the distribution of organic pollutants in surface sediments from a Mediterranean coastal lagoon (Mar Menor, SE Spain). Environ Sci Pollut Res Int 2017; 24:4284-4300. [PMID: 25960016 DOI: 10.1007/s11356-015-4628-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/29/2015] [Accepted: 04/27/2015] [Indexed: 06/04/2023]
Abstract
The influence of flash flood events on the input and distribution of polycyclic aromatic hydrocarbons (PAHs), polychlorinated biphenyls (PCBs), and organochlorinated pesticides (OCPs) in surface sediments from the Mar Menor lagoon were characterized in this study. These contaminants were analyzed in surface water samples collected during two flash flood events in the main surface watercourse which flow into the Mar Menor lagoon. Surface sediments were sampled semiannually before and after flash flood events. The total input of PAHs, OCPs, and PCBs (sorbed + dissolved) during two flash flood events was estimated at 0.98, 1.32, and 0.34 kg, respectively, the main input corresponding to p,p'-DDE (1.00 kg). The distribution of organic contaminants in surface sediments was not homogeneous as a consequence of the presence of many simultaneous sources and different meteorological, hydrodynamic, and physicochemical conditions. As a consequence of flash flood events, p,p'-DDE concentrations in surface sediments increased significantly in the central and south zones of the lagoon. However, in the case of PCBs, a dilution effect was observed in the south zone after such events, reducing the environmental risk. These changes in the pollutant distribution persisted at least 1 year later (autumn 2010), showing that the impact of flood events in the distribution of persistent organic contaminants in Mediterranean coastal lagoons is of relevance according to the ecological risk assessment carried out. The impact of these events should be also considered in other coastal systems, especially in semiarid and semiconfined areas.
Collapse
Affiliation(s)
- V M León
- Instituto Español de Oceanografía, Centro Oceanográfico de Murcia, Apdo. 22, C/ Varadero 1, 30740, San Pedro del Pinatar, Murcia, Spain.
| | - R Moreno-González
- Instituto Español de Oceanografía, Centro Oceanográfico de Murcia, Apdo. 22, C/ Varadero 1, 30740, San Pedro del Pinatar, Murcia, Spain
| | - V García
- Instituto Español de Oceanografía, Centro Oceanográfico de Murcia, Apdo. 22, C/ Varadero 1, 30740, San Pedro del Pinatar, Murcia, Spain
| | - J A Campillo
- Instituto Español de Oceanografía, Centro Oceanográfico de Murcia, Apdo. 22, C/ Varadero 1, 30740, San Pedro del Pinatar, Murcia, Spain
| |
Collapse
|
|
16
|
García V, Sánchez JS, Cleofas-Sánchez L, Ochoa-Domínguez HJ, López-Orozco F. An Insight on the ‘Large G, Small n’ Problem in Gene-Expression Microarray Classification. Pattern Recognition and Image Analysis 2017. [DOI: 10.1007/978-3-319-58838-4_53] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
|
17
|
Cleofas-Sánchez L, García V, Marqués A, Sánchez J. Financial distress prediction using the hybrid associative memory with translation. Appl Soft Comput 2016. [DOI: 10.1016/j.asoc.2016.04.005] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
|
18
|
Miarons M, García V, Moreno Q, Marín S, Camps M, Sánchez A, Agustí C, Gurrera T, Campins L. PS-011 Impact of pharmaceutical interventions on medication errors in preparation of chemotherapy regimens. Eur J Hosp Pharm 2016. [DOI: 10.1136/ejhpharm-2016-000875.496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
|
19
|
Miarons M, Martínez S, García V, Marin S, Camps ML, Agustí C, Gurrera T. CP-208 Pegylated liposomal doxorubicin and carboplatine combination in the treatment of recurrent ovarian carcinoma. Comparative long term effectiveness. Eur J Hosp Pharm 2016. [DOI: 10.1136/ejhpharm-2016-000875.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
|
20
|
Moreno M, Cabañes L, de Blas G, Antón L, García V, Burgos J. ID 136 – Accidental spinal cord contusions during spine deformity surgeries. Clin Neurophysiol 2016. [DOI: 10.1016/j.clinph.2015.11.343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
|
21
|
García V, Camps M, Moreno Q, Miarons M, Campins L, Sánchez A, Marín S, Gurrera T, Fábregas X, Agustí C. PS-002 New oral therapies in relapsing-remitting multiple sclerosis: Safety profile evaluation. Eur J Hosp Pharm 2016. [DOI: 10.1136/ejhpharm-2016-000875.487] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
|
22
|
Cambra MJ, Moreno F, Sanz X, Anglada L, Moià M, Reyes V, Arenas M, Pedro A, Ballester R, García V, Sanjosé S, Cusidó M, Jimenez C, Macià M, Solé JM, Farrus B. Abstract P5-17-08: Study of boost radiotherapy's influence on local control in 646 pure ductal carcinoma in situ breast cancer with long-term follow-up. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-17-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Boost radiotherapy (B-RT) improves outcome in patients (pts) with invasive breast cancer. It's use in patients with pure ductal carcinoma in situ (DCIS) is unclear. There are two ongoing randomize trials, results are expected in ten years. Twelve retrospective observational studies have been published since 2006, the recent meta-analysis, support boost in the presence of positive margins.
PATIENTS and METHODS: We analyse a retrospective women's cohort of 646 pure DCIS patients (pts) treated mainly in two Hospitals (n=518) from 1993 to 2014. The other ten Hospitals included 128 pts all 2005 long. Proportions were compared by boost status, using the chi-square tests. The impact of boost radiation on the development of local recurrence (LR) was determined using survival analyses. In the comparison of Kaplan-Meier (K-M) was used log-rank test.
RESULTS: B-RT subgroup is 394 pts (61%), noB-RT 252 (39%). Median follow-up (FU) is 8.8 years. High risk factors: young age, size, margin status and tamoxifen (TMX) show differences among B-RT (p<0.05). 46% were Estrogen Receptor positive (ER+), 30% B-RT and 16% noB-RT. 22% RE+ in B-RT take TMX vs 9.4 % RE+ noB-RT. Total LR 65 (10%). In situ LR 30 pts (4,6%) and Invasive (Inv) 35 (5,4%). By subgroup, LR in B-RT 47 (12%) vs. 18 (7%) in noB-RT. By subtype, In situ LR in B-RT 20 (5.1%) vs. noB-RT 10 (4%). Inv LR in B-RT 27 (6.9%) vs. noB-RT 8 (3.2%). In uni & multivariate analysis, tumour size, Re-Excision, and TMX, are significant LR risk factors (p<0.05). Boost total doses >16 Gy in the B-RT subgroup is a LR significant risk factor related to 10-16 Gy (p∼0.05). TMX and Dose Boost are related (p<0.001). When Dose is introduced in multivariate analysis model, TMX lost signification. Contralateral local recurrence (CLR) in 29 pts (7%). Second tumours 9 pts (NSD between subgroups). Global disease free survival (DFS) is 80.5%, 77% in B-RT vs. 85% in noB-RT. Four pts have a LR combined with CLR; 2 pts have a LR and a second tumor; 1 pt with CLR and second tumour; 1 pt a Inv regional recurrence; 1 pt mixosarcoma in ipsilateral breast and lung metastases. Deaths: 3 pts (0.5%) after an Inv LR; 3 pts (0.5%) after Inv CR; 20 pts other causes; 10 pts lost their FU. Median FU in B-RT subgroup was 9y vs. 8.3y in noB-RT. The maximum FU according LR in B-RT is 20.6y vs. 17.4y in noB-RT. RL is not significant according to Boost (K-M p=0.398). Median LR in situ or inv depending of B-RT vs. noB-RT shows NSD (p=0.663).
CONCLUSIONS: In this large cohort retrospective study with long-term follow-up B-RT was associated with similar LR as noB-RT despite being used more frequently with higher risk disease. Dose boost >16 Gy has a protective effect. Tamoxifen and boost dose are related variables. Further evidence, based on ongoing randomized trials results is essential.
Citation Format: Cambra MJ, Moreno F, Sanz X, Anglada L, Moià M, Reyes V, Arenas M, Pedro A, Ballester R, García V, Sanjosé S, Cusidó M, Jimenez C, Macià M, Solé JM, Farrus B. Study of boost radiotherapy's influence on local control in 646 pure ductal carcinoma in situ breast cancer with long-term follow-up. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-17-08.
Collapse
Affiliation(s)
- MJ Cambra
- Institut Oncològic del Vallés-IDC-HGC, Sant Cugat del Vallés, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain; Hospital de la Esperança. Parc de Salut Mar, Barcelona, Spain; Institut Català d'Oncologia, Girona, Spain; Hospital Universitari de la Vall de Hebrón, Barcelona, Spain; Hospital Universitari Sant Joan, Reus, Tarragona, Spain; Hospital Plató, Barcelona, Spain; Institut Català d'Oncologia, Badalona, Spain; Hospital Universitari Arnau de Vilanova, Lleida, Spain; Hospital Quirón, Barcelona, Spain; Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain; Hospital Clìnic i Provincial, Barcelona, Spain
| | - F Moreno
- Institut Oncològic del Vallés-IDC-HGC, Sant Cugat del Vallés, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain; Hospital de la Esperança. Parc de Salut Mar, Barcelona, Spain; Institut Català d'Oncologia, Girona, Spain; Hospital Universitari de la Vall de Hebrón, Barcelona, Spain; Hospital Universitari Sant Joan, Reus, Tarragona, Spain; Hospital Plató, Barcelona, Spain; Institut Català d'Oncologia, Badalona, Spain; Hospital Universitari Arnau de Vilanova, Lleida, Spain; Hospital Quirón, Barcelona, Spain; Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain; Hospital Clìnic i Provincial, Barcelona, Spain
| | - X Sanz
- Institut Oncològic del Vallés-IDC-HGC, Sant Cugat del Vallés, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain; Hospital de la Esperança. Parc de Salut Mar, Barcelona, Spain; Institut Català d'Oncologia, Girona, Spain; Hospital Universitari de la Vall de Hebrón, Barcelona, Spain; Hospital Universitari Sant Joan, Reus, Tarragona, Spain; Hospital Plató, Barcelona, Spain; Institut Català d'Oncologia, Badalona, Spain; Hospital Universitari Arnau de Vilanova, Lleida, Spain; Hospital Quirón, Barcelona, Spain; Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain; Hospital Clìnic i Provincial, Barcelona, Spain
| | - L Anglada
- Institut Oncològic del Vallés-IDC-HGC, Sant Cugat del Vallés, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain; Hospital de la Esperança. Parc de Salut Mar, Barcelona, Spain; Institut Català d'Oncologia, Girona, Spain; Hospital Universitari de la Vall de Hebrón, Barcelona, Spain; Hospital Universitari Sant Joan, Reus, Tarragona, Spain; Hospital Plató, Barcelona, Spain; Institut Català d'Oncologia, Badalona, Spain; Hospital Universitari Arnau de Vilanova, Lleida, Spain; Hospital Quirón, Barcelona, Spain; Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain; Hospital Clìnic i Provincial, Barcelona, Spain
| | - M Moià
- Institut Oncològic del Vallés-IDC-HGC, Sant Cugat del Vallés, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain; Hospital de la Esperança. Parc de Salut Mar, Barcelona, Spain; Institut Català d'Oncologia, Girona, Spain; Hospital Universitari de la Vall de Hebrón, Barcelona, Spain; Hospital Universitari Sant Joan, Reus, Tarragona, Spain; Hospital Plató, Barcelona, Spain; Institut Català d'Oncologia, Badalona, Spain; Hospital Universitari Arnau de Vilanova, Lleida, Spain; Hospital Quirón, Barcelona, Spain; Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain; Hospital Clìnic i Provincial, Barcelona, Spain
| | - V Reyes
- Institut Oncològic del Vallés-IDC-HGC, Sant Cugat del Vallés, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain; Hospital de la Esperança. Parc de Salut Mar, Barcelona, Spain; Institut Català d'Oncologia, Girona, Spain; Hospital Universitari de la Vall de Hebrón, Barcelona, Spain; Hospital Universitari Sant Joan, Reus, Tarragona, Spain; Hospital Plató, Barcelona, Spain; Institut Català d'Oncologia, Badalona, Spain; Hospital Universitari Arnau de Vilanova, Lleida, Spain; Hospital Quirón, Barcelona, Spain; Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain; Hospital Clìnic i Provincial, Barcelona, Spain
| | - M Arenas
- Institut Oncològic del Vallés-IDC-HGC, Sant Cugat del Vallés, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain; Hospital de la Esperança. Parc de Salut Mar, Barcelona, Spain; Institut Català d'Oncologia, Girona, Spain; Hospital Universitari de la Vall de Hebrón, Barcelona, Spain; Hospital Universitari Sant Joan, Reus, Tarragona, Spain; Hospital Plató, Barcelona, Spain; Institut Català d'Oncologia, Badalona, Spain; Hospital Universitari Arnau de Vilanova, Lleida, Spain; Hospital Quirón, Barcelona, Spain; Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain; Hospital Clìnic i Provincial, Barcelona, Spain
| | - A Pedro
- Institut Oncològic del Vallés-IDC-HGC, Sant Cugat del Vallés, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain; Hospital de la Esperança. Parc de Salut Mar, Barcelona, Spain; Institut Català d'Oncologia, Girona, Spain; Hospital Universitari de la Vall de Hebrón, Barcelona, Spain; Hospital Universitari Sant Joan, Reus, Tarragona, Spain; Hospital Plató, Barcelona, Spain; Institut Català d'Oncologia, Badalona, Spain; Hospital Universitari Arnau de Vilanova, Lleida, Spain; Hospital Quirón, Barcelona, Spain; Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain; Hospital Clìnic i Provincial, Barcelona, Spain
| | - R Ballester
- Institut Oncològic del Vallés-IDC-HGC, Sant Cugat del Vallés, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain; Hospital de la Esperança. Parc de Salut Mar, Barcelona, Spain; Institut Català d'Oncologia, Girona, Spain; Hospital Universitari de la Vall de Hebrón, Barcelona, Spain; Hospital Universitari Sant Joan, Reus, Tarragona, Spain; Hospital Plató, Barcelona, Spain; Institut Català d'Oncologia, Badalona, Spain; Hospital Universitari Arnau de Vilanova, Lleida, Spain; Hospital Quirón, Barcelona, Spain; Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain; Hospital Clìnic i Provincial, Barcelona, Spain
| | - V García
- Institut Oncològic del Vallés-IDC-HGC, Sant Cugat del Vallés, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain; Hospital de la Esperança. Parc de Salut Mar, Barcelona, Spain; Institut Català d'Oncologia, Girona, Spain; Hospital Universitari de la Vall de Hebrón, Barcelona, Spain; Hospital Universitari Sant Joan, Reus, Tarragona, Spain; Hospital Plató, Barcelona, Spain; Institut Català d'Oncologia, Badalona, Spain; Hospital Universitari Arnau de Vilanova, Lleida, Spain; Hospital Quirón, Barcelona, Spain; Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain; Hospital Clìnic i Provincial, Barcelona, Spain
| | - S Sanjosé
- Institut Oncològic del Vallés-IDC-HGC, Sant Cugat del Vallés, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain; Hospital de la Esperança. Parc de Salut Mar, Barcelona, Spain; Institut Català d'Oncologia, Girona, Spain; Hospital Universitari de la Vall de Hebrón, Barcelona, Spain; Hospital Universitari Sant Joan, Reus, Tarragona, Spain; Hospital Plató, Barcelona, Spain; Institut Català d'Oncologia, Badalona, Spain; Hospital Universitari Arnau de Vilanova, Lleida, Spain; Hospital Quirón, Barcelona, Spain; Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain; Hospital Clìnic i Provincial, Barcelona, Spain
| | - M Cusidó
- Institut Oncològic del Vallés-IDC-HGC, Sant Cugat del Vallés, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain; Hospital de la Esperança. Parc de Salut Mar, Barcelona, Spain; Institut Català d'Oncologia, Girona, Spain; Hospital Universitari de la Vall de Hebrón, Barcelona, Spain; Hospital Universitari Sant Joan, Reus, Tarragona, Spain; Hospital Plató, Barcelona, Spain; Institut Català d'Oncologia, Badalona, Spain; Hospital Universitari Arnau de Vilanova, Lleida, Spain; Hospital Quirón, Barcelona, Spain; Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain; Hospital Clìnic i Provincial, Barcelona, Spain
| | - C Jimenez
- Institut Oncològic del Vallés-IDC-HGC, Sant Cugat del Vallés, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain; Hospital de la Esperança. Parc de Salut Mar, Barcelona, Spain; Institut Català d'Oncologia, Girona, Spain; Hospital Universitari de la Vall de Hebrón, Barcelona, Spain; Hospital Universitari Sant Joan, Reus, Tarragona, Spain; Hospital Plató, Barcelona, Spain; Institut Català d'Oncologia, Badalona, Spain; Hospital Universitari Arnau de Vilanova, Lleida, Spain; Hospital Quirón, Barcelona, Spain; Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain; Hospital Clìnic i Provincial, Barcelona, Spain
| | - M Macià
- Institut Oncològic del Vallés-IDC-HGC, Sant Cugat del Vallés, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain; Hospital de la Esperança. Parc de Salut Mar, Barcelona, Spain; Institut Català d'Oncologia, Girona, Spain; Hospital Universitari de la Vall de Hebrón, Barcelona, Spain; Hospital Universitari Sant Joan, Reus, Tarragona, Spain; Hospital Plató, Barcelona, Spain; Institut Català d'Oncologia, Badalona, Spain; Hospital Universitari Arnau de Vilanova, Lleida, Spain; Hospital Quirón, Barcelona, Spain; Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain; Hospital Clìnic i Provincial, Barcelona, Spain
| | - JM Solé
- Institut Oncològic del Vallés-IDC-HGC, Sant Cugat del Vallés, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain; Hospital de la Esperança. Parc de Salut Mar, Barcelona, Spain; Institut Català d'Oncologia, Girona, Spain; Hospital Universitari de la Vall de Hebrón, Barcelona, Spain; Hospital Universitari Sant Joan, Reus, Tarragona, Spain; Hospital Plató, Barcelona, Spain; Institut Català d'Oncologia, Badalona, Spain; Hospital Universitari Arnau de Vilanova, Lleida, Spain; Hospital Quirón, Barcelona, Spain; Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain; Hospital Clìnic i Provincial, Barcelona, Spain
| | - B Farrus
- Institut Oncològic del Vallés-IDC-HGC, Sant Cugat del Vallés, Barcelona, Spain; Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain; Hospital de la Esperança. Parc de Salut Mar, Barcelona, Spain; Institut Català d'Oncologia, Girona, Spain; Hospital Universitari de la Vall de Hebrón, Barcelona, Spain; Hospital Universitari Sant Joan, Reus, Tarragona, Spain; Hospital Plató, Barcelona, Spain; Institut Català d'Oncologia, Badalona, Spain; Hospital Universitari Arnau de Vilanova, Lleida, Spain; Hospital Quirón, Barcelona, Spain; Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain; Hospital Clìnic i Provincial, Barcelona, Spain
| |
Collapse
|
|
23
|
Ben Salem R, Abbassi M, García V, García-Fierro R, Njoud C, Messadi L, Rodicio MR. Detection and Molecular Characterization ofSalmonella entericaSerovar Eppendorf Circulating in Chicken Farms in Tunisia. Zoonoses Public Health 2015; 63:320-7. [DOI: 10.1111/zph.12234] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2015] [Indexed: 11/30/2022]
Affiliation(s)
- R. Ben Salem
- Veterinary Research Institute of Tunisia; Tunis Tunisia
- Faculty of Sciences of Bizert; University of Carthage; Bizert Tunisia
| | - M.S. Abbassi
- Veterinary Research Institute of Tunisia; Tunis Tunisia
| | - V. García
- Departamento de Biología Funcional; Área de Microbiología; Universidad de Oviedo; Oviedo Spain
| | - R. García-Fierro
- Departamento de Biología Funcional; Área de Microbiología; Universidad de Oviedo; Oviedo Spain
| | - C. Njoud
- Regional Center of Veterinary Research; Sousse Tunisia
| | - L. Messadi
- National School of Veterinary Medicine; Department of Microbiology and Immunology; University of La Manouba; Sidi Thabet Tunisia
| | - M. R. Rodicio
- Departamento de Biología Funcional; Área de Microbiología; Universidad de Oviedo; Oviedo Spain
| |
Collapse
|
|
24
|
Abstract
Hyperandrogenemia, hyperinsulinemia, and obesity affect 60-70% of patients with Polycystic Ovarian Syndrome (PCOS), who exhibit an altered endometrial insulin signaling. The aim of the study was to evaluate whether hyperandrogenism, hyperinsulinism, and obesity present in PCOS patients impair the endometrial adiponectin signaling pathway. The ex vivo study was conducted on 27 samples from lean (n=9), obese (n=9), and obese-PCOS (n=9) patients. The in vitro assays were performed in immortalized human endometrial stromal cells stimulated with testosterone, insulin, or testosterone plus insulin. Serum steroid-hormones, adiponectin, glucose, and insulin; body mass index, free androgen index, ISI-Composite, and HOMA were evaluated in the 3 groups. Ex vivo and in vitro gene expression and protein content of adiponectin, AdipoR1, AdipoR2, and APPL1 were determined. Adiponectin serum levels were decreased in obese-PCOS patients compared to lean (78%) and obese (54%) controls (p<0.05). AdipoR1 protein and gene expression were increased in obese group vs. obese-PCOS and lean groups (2-fold, p<0.05). In turn, AdipoR2 protein and mRNA content was similar between the 3 groups. APPL1 protein levels were reduced in endometria from both obese groups, compared to lean group (6-fold, p<0.05). Testosterone plus insulin stimulation of T-HESC and St-T1b leads to a reduction of adiponectin, AdipoR1, AdipoR2, and APPL1 protein content in both endometrial cell lines (p<0.05), whereas, in the presence of testosterone or insulin alone, protein levels were similar to basal. Therefore, endometrial adiponectin-signaling pathway is impaired in hyperandrogenemic and hyperinsulinemic obese-PCOS patients, corroborated in the in vitro model, which could affect endometrial function and potentially the implantation process.
Collapse
Affiliation(s)
- V García
- Laboratory of Endocrinology and Reproductive Biology, University of Chile Clinical Hospital, Santiago, Chile
| | - L Oróstica
- Laboratory of Endocrinology and Reproductive Biology, University of Chile Clinical Hospital, Santiago, Chile
| | - C Poblete
- Laboratory of Endocrinology and Reproductive Biology, University of Chile Clinical Hospital, Santiago, Chile
| | - C Rosas
- Laboratory of Endocrinology and Reproductive Biology, University of Chile Clinical Hospital, Santiago, Chile
| | - I Astorga
- Laboratory of Endocrinology and Reproductive Biology, University of Chile Clinical Hospital, Santiago, Chile
| | - C Romero
- Laboratory of Endocrinology and Reproductive Biology, University of Chile Clinical Hospital, Santiago, Chile
| | - M Vega
- Laboratory of Endocrinology and Reproductive Biology, University of Chile Clinical Hospital, Santiago, Chile
| |
Collapse
|
|
25
|
Alonso A, Tornero J, Nebro A, Cañete J, Domènech E, Gisbert J, Ferrándiz C, Fonseca E, García V, Blanco F, Rodríguez J, Gratacόs J, Carreira P, Tortosa R, Lόpez-Lasanta M, Julià A, Correig X, Marsal S. OP0072 Identification and Validation of Diagnostic and Activity Urinary Metabolomic Biomarkers in Immune-Mediated Inflammatory Diseases. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
|
26
|
Laso J, García V, Bringas E, Urtiaga AM, Ortiz I. Selective Recovery of Zinc over Iron from Spent Pickling Wastes by Different Membrane-based Solvent Extraction Process Configurations. Ind Eng Chem Res 2015. [DOI: 10.1021/acs.iecr.5b00099] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- J. Laso
- Department of Chemical and
Biomolecular Engineering, University of Cantabria, Av. de los
Castros s/n, 39005 Santander, Spain
| | - V. García
- Department of Chemical and
Biomolecular Engineering, University of Cantabria, Av. de los
Castros s/n, 39005 Santander, Spain
| | - E. Bringas
- Department of Chemical and
Biomolecular Engineering, University of Cantabria, Av. de los
Castros s/n, 39005 Santander, Spain
| | - A. M. Urtiaga
- Department of Chemical and
Biomolecular Engineering, University of Cantabria, Av. de los
Castros s/n, 39005 Santander, Spain
| | - I. Ortiz
- Department of Chemical and
Biomolecular Engineering, University of Cantabria, Av. de los
Castros s/n, 39005 Santander, Spain
| |
Collapse
|
|
27
|
Camps M, Miarons M, García V, Moreno Q, Campins L, Agustí C, Lopez D, Sánchez A, Fabregas X, Lavado A. PS-090 Results of a medicines reconciliation program in complex chronic patients at hospital discharge. Eur J Hosp Pharm 2015. [DOI: 10.1136/ejhpharm-2015-000639.413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
|
28
|
Gutiérrez-Capitán M, Baldi A, Gómez R, García V, Jiménez-Jorquera C, Fernández-Sánchez C. Electrochemical Nanocomposite-Derived Sensor for the Analysis of Chemical Oxygen Demand in Urban Wastewaters. Anal Chem 2015; 87:2152-60. [DOI: 10.1021/ac503329a] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Manuel Gutiérrez-Capitán
- Instituto de Microelectrónica de Barcelona (IMB-CNM), CSIC, Campus de la UAB s/n, Bellaterra, Barcelona 08193, Spain
| | - Antoni Baldi
- Instituto de Microelectrónica de Barcelona (IMB-CNM), CSIC, Campus de la UAB s/n, Bellaterra, Barcelona 08193, Spain
| | - Raquel Gómez
- Adasa Sistemas S.A., C/José Agustín
Goytisolo 30-32, L’Hospitalet de Llobregat, Barcelona 08908, Spain
| | - Virginia García
- Adasa Sistemas S.A., C/José Agustín
Goytisolo 30-32, L’Hospitalet de Llobregat, Barcelona 08908, Spain
| | - Cecilia Jiménez-Jorquera
- Instituto de Microelectrónica de Barcelona (IMB-CNM), CSIC, Campus de la UAB s/n, Bellaterra, Barcelona 08193, Spain
| | - César Fernández-Sánchez
- Instituto de Microelectrónica de Barcelona (IMB-CNM), CSIC, Campus de la UAB s/n, Bellaterra, Barcelona 08193, Spain
| |
Collapse
|
|
29
|
Vila L, García V. Oral tolerance induction with wheat: a valid therapeutic option in allergic patients. J Investig Allergol Clin Immunol 2015; 25:77-78. [PMID: 25898707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023] Open
|
|
30
|
García V, Sánchez JS, Ochoa Domínguez HJ, Cleofas-Sánchez L. Dissimilarity-Based Learning from Imbalanced Data with Small Disjuncts and Noise. Pattern Recognition and Image Analysis 2015. [DOI: 10.1007/978-3-319-19390-8_42] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
|
31
|
García V, Rovira S, Boutoial K, Álvarez D, López MB. A comparison of the use of thistle (Cynara cardunculus L.) and artichoke (Cynara scolymus L.) aqueous extracts for milk coagulation. ACTA ACUST UNITED AC 2014. [DOI: 10.1007/s13594-014-0197-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
|
32
|
Alejo R, García V, Pacheco-Sánchez JH. An Efficient Over-sampling Approach Based on Mean Square Error Back-propagation for Dealing with the Multi-class Imbalance Problem. Neural Process Lett 2014. [DOI: 10.1007/s11063-014-9376-3] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
|
33
|
Alonso A, Tornero J, Fernández Nebro A, Cañete J, Domènech E, Gisbert J, Ferrándiz C, Fonseca E, García V, Blanco F, Rodríguez J, Gratacόs J, Carreira P, Julià A, Tortosa R, Lasanta M, Correig X, Marsal S. OP0189 Identification of Disease Diagnostic and Disease Activity Metabolomic Biomarkers in Immune-Mediated Inflammatory Diseases. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.4927] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
|
34
|
Cortés V, Cabañes L, Álvarez J, de Blas G, Barrios C, García V, Burgos J. P501: Value of stimulus-triggered EMG of track vs screw for the detection of lumbar radiculopathy in scoliosis surgery. Clin Neurophysiol 2014. [DOI: 10.1016/s1388-2457(14)50598-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
|
35
|
García-Antón J, Fernández-Domene R, Sánchez-Tovar R, Escrivà-Cerdán C, Leiva-García R, García V, Urtiaga A. Improvement of the electrochemical behaviour of Zn-electroplated steel using regenerated Cr (III) passivation baths. Chem Eng Sci 2014. [DOI: 10.1016/j.ces.2014.03.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
|
36
|
Martinuzzi A, Ferraresi E, Orsati M, Palaoro A, Chaparro J, Alcántara S, Amin C, Feller C, Di Leo ME, Guillot A, García V. [Impact of quality improvement process upon the state of nutritional support in a critical care unit]. NUTR HOSP 2013; 27:1219-27. [PMID: 23165565 DOI: 10.3305/nh.2012.27.4.5817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2012] [Accepted: 03/02/2012] [Indexed: 12/01/2022] Open
Abstract
INTRODUCTION In a preceding article the state of Nutritional support (NS) in an Intensive Care Unit (ICU) was documented [Martinuzzi A et al. Estado del soporte nutricional en una unidad de Cuidados críticos. RNC 2011; 20: 5-17]. In this follow-up work we set to assess the impact of several organizational, recording and educational interventions upon the current state of NS processes. MATERIALS AND METHODS Interventions comprised presentation of the results of the audit conducted at the ICU before the institution's medical as well as paramedical personnel; their publication in a periodical, peer-reviewed journal; drafting and implementation of a protocol regulating NS schemes to be carried out at the ICU; and conduction of continuous education activities on Nutrition (such as "experts talks", interactive courses, and training in the implementation of the NS protocol). The state of NS processes documented after the interventions was compared with the results annotated in the preceding article. Study observation window ran between March the 1st, 2011 and May 31th, 2011, both included. RESULTS Study series differed only regarding overall-mortality: Phase 1: 40.0% vs. Phase 2: 20.5%; Difference: 19.5%; Z = 1.927; two-tailed-p = 0.054. Interventions resulted in a higher fulfillment rate of the prescribed NS indication; an increase in the number of patients receiving ≥ 80% of prescribed energy; and a reduction in the number of NS lost days. Mortality was (numerically) lower in patients in which the prescribed NS scheme was fulfilled, NS was early initiated, and whom received ≥ 80% of prescribed energy. Adopted interventions had no effect upon average energy intakes: Phase 1: 574.7 ± 395.3 kcal/24 h⁻¹ vs. Phase 2: 591.1 ± 315.3 kcal/24 h⁻¹; two-tailed-p > 0.05. CONCLUSIONS Educational, recording and organizational interventions might result in a better conduction of NS processes, and thus, in a lower mortality. Hemodynamic instability is still the most formidable obstacle for initiating and completing NS.
Collapse
Affiliation(s)
- A Martinuzzi
- Unidad de Cuidados Críticos, HIGA, Hospital Interzonal General de Agudos Dr. Rodolfo Rossi, La Plata, Buenos Aires, Argentina.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
37
|
Díaz V, López D, García V, Moreno M, Sánchez G, Sánchez F. Resultados a largo plazo de prótesis de cúbito distal como cirugía de rescate en un caso de técnica de Sauvé-Kapandji fallida. Rev Iberoam Cir Mano 2013. [DOI: 10.1055/s-0037-1607086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Abstract
La técnica de Sauvé-Kapandji se emplea como tratamiento de rescate en la patología de la articulación radiocubital distal (ARCD). Los resultados postoperatorios son buenos, aunque a largo plazo pueden surgir complicaciones como dolor, muñón cubital inestable y pérdida de fuerza de prensión. Presentamos un caso de cirugía de rescate de esta técnica mediante prótesis de cúbito distal. A los cuatro años de seguimiento, el paciente presenta desaparición completa del dolor y recuperación de la fuerza de prensión, lo que hace pensar que la prótesis cubital puede ser un buen método de rescate cuando fracasa un Sauvé-Kapandji.
Collapse
Affiliation(s)
- V. Díaz
- Servicio de Cirugía Ortopédica y Traumatología. Hospital Universitario Doce de Octubre. Madrid. España
| | - D. López
- Servicio de Cirugía Ortopédica y Traumatología. Hospital Universitario Doce de Octubre. Madrid. España
| | - V. García
- Servicio de Cirugía Ortopédica y Traumatología. Hospital Txagorritxu de Vitoria. España
| | - M. Moreno
- Servicio de Cirugía Ortopédica y Traumatología. Hospital Universitario Doce de Octubre. Madrid. España
| | - G. Sánchez
- Servicio de Cirugía Ortopédica y Traumatología. Hospital Universitario Doce de Octubre. Madrid. España
| | - F. Sánchez
- Servicio de Cirugía Ortopédica y Traumatología. Hospital Universitario Doce de Octubre. Madrid. España
| |
Collapse
|
|
38
|
Obregón L, Ruiz-Castilla M, Binimelis MM, Guinot A, García V, Puig O, Barret JP. Laparoscopic repair of non-complicated lumbar hernia secondary to a latissimus dorsi flap. J Plast Reconstr Aesthet Surg 2013; 67:407-10. [PMID: 23910913 DOI: 10.1016/j.bjps.2013.07.022] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2013] [Accepted: 07/09/2013] [Indexed: 11/28/2022]
Abstract
UNLABELLED Lumbar hernia is an unusual complication of the latissimus dorsi flap. Traditionally, it has always been repaired using open-surgery techniques. We present the first description of laparoscopic surgery to treat a non-complicated superior lumbar hernia resulting from the creation of an enlarged latissimus dorsi myocutaneous flap for breast reconstruction following left modified radical mastectomy. The laparoscopic approach substantially reduced the risks associated with open surgery, shortened length of hospital stay and time to recovery and obtained better cosmetic results. Laparoscopic surgery may be considered as a feasible therapeutic option for non-complicated superior lumbar hernias secondary to a latissimus dorsi muscle flap. CLINICAL QUESTION/LEVEL OF EVIDENCE Therapeutic, V.
Collapse
Affiliation(s)
- L Obregón
- Plastic and Reconstructive Surgery Department and Burns Unit, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - M Ruiz-Castilla
- Plastic and Reconstructive Surgery Department and Burns Unit, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
| | - M M Binimelis
- Plastic and Reconstructive Surgery Department and Burns Unit, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - A Guinot
- Plastic and Reconstructive Surgery Department and Burns Unit, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - V García
- Plastic and Reconstructive Surgery Department and Burns Unit, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - O Puig
- Surgery Department, Vall d'Hebron University Hospital, Barcelona, Spain
| | - J P Barret
- Plastic and Reconstructive Surgery Department and Burns Unit, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain
| |
Collapse
|
|
39
|
Moreno-González R, Campillo JA, García V, León VM. Seasonal input of regulated and emerging organic pollutants through surface watercourses to a Mediterranean coastal lagoon. Chemosphere 2013; 92:247-257. [PMID: 23399306 DOI: 10.1016/j.chemosphere.2012.12.022] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/19/2011] [Revised: 11/22/2012] [Accepted: 12/15/2012] [Indexed: 06/01/2023]
Abstract
Seasonal input of organic pollutants through El Albujón Watercourse to the Mar Menor lagoon was estimated from Spring 2009 to Winter 2010, including regular periods and two flash flood events. 82 semivolatile organic pollutants (persistent organic pollutants, different groups of pesticides and others) were determined by stir bar sorptive extraction and thermal desorption followed by capillary gas chromatography coupled to mass spectrometry from surface waters with quantification limits of a few ngL(-1). Pesticide concentrations varied significantly along the watercourse due to the presence of different sources (groundwaters, wastewater effluent, tributary contributions, brackish waters, etc.) and physicochemical/biological processes that take place simultaneously. The most commonly detected analytes were propyzamide, triazine compounds and chlorpyrifos. A clear seasonal pattern has been detected, with a predominance of insecticides during Summer and of herbicides during Winter. The input of pesticides through this watercourse is particularly relevant during periods of heavy rain, representing more than 70% of total yearly input for many of them.
Collapse
Affiliation(s)
- R Moreno-González
- Instituto Español de Oceanografía, Centro Oceanográfico de Murcia, Apdo. 22, C/Varadero 1, 30740 San Pedro del Pinatar, Murcia, Spain.
| | | | | | | |
Collapse
|
|
40
|
Cambra Serés M, Frarrús B, Moreno F, Anglada L, Arenas M, Ballester R, Casals J, Cusido M, García V, Gutierrez C, Pedro A, Reyes V, Sanz X. Best oral presentation: Comparative management of breast ductal carcinoma in situ: Goco-Praccis-Catalunya (2004-0001) Praccis–France. Rep Pract Oncol Radiother 2013. [DOI: 10.1016/j.rpor.2013.03.716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
|
41
|
Sangorrín MP, García V, Lopes CA, Sáez JS, Martínez C, Ganga MA. Molecular and physiological comparison of spoilage wine yeasts. J Appl Microbiol 2013; 114:1066-74. [PMID: 23311591 DOI: 10.1111/jam.12134] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2012] [Revised: 11/21/2012] [Accepted: 12/11/2012] [Indexed: 11/27/2022]
Abstract
AIMS Dekkera bruxellensis and Pichia guilliermondii are contaminating yeasts in wine due to the production of phenolic aromas. Although the degradation pathway of cinnamic acids, precursors of these phenolic compounds has been described in D. bruxellensis, no such pathway has been described in P. guilliermondii. METHODS AND RESULTS A molecular and physiological characterization of 14 D. bruxellensis and 15 P. guilliermondii phenol-producing strains was carried out. Both p-coumarate decarboxylase (CD) and vinyl reductase (VR) activities, responsible for the production of volatile phenols, were quantified and the production of 4-vinylphenol and 4-ethylphenol were measured. All D. bruxellensis and some P. guilliermondii strains showed the two enzymatic activities, whilst 11 of the 15 strains of this latter species showed only CD activity and did not produce 4-EP in the assay conditions. Furthermore, PCR products obtained with degenerated primers showed a low homology with the sequence of the gene for a phenyl acrylic acid decarboxylase activity described in Saccharomyces cerevisiae. CONCLUSIONS D. bruxellensis and P. guilliermondii may share a similar metabolic pathway for the degradation of cinnamic acids. SIGNIFICANCE AND IMPACT OF THE STUDY This is the first work that analyses the CD and VR activities in P. guilliermondii, and the results suggest that within this species, there are differences in the metabolization of cinnamic acids.
Collapse
Affiliation(s)
- M P Sangorrín
- Grupo de Biodiversidad y Biotecnología de Levaduras, Instituto Multidisciplinario de Investigación y Desarrollo de la Patagonia Norte (IDEPA CONICET-UNCo), Dpto. de Química, Facultad de Ingeniería, Universidad Nacional del Comahue, Buenos Aires, Argentina
| | | | | | | | | | | |
Collapse
|
|
42
|
Millán-Giraldo M, García V, Sánchez JS. Instance Selection Methods and Resampling Techniques for Dissimilarity Representation with Imbalanced Data Sets. ACTA ACUST UNITED AC 2013. [DOI: 10.1007/978-3-642-36530-0_12] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
|
|
43
|
Rovira S, García V, Ferrandini E, Carrión J, Castillo M, López MB. Usefulness of a large field of view sensor for physicochemical, textural, and yield predictions under industrial goat cheese (Murcia al Vino) manufacturing conditions. J Dairy Sci 2012; 95:6320-31. [PMID: 22981571 DOI: 10.3168/jds.2012-5561] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2012] [Accepted: 07/12/2012] [Indexed: 11/19/2022]
Abstract
The applicability of a light backscatter sensor with a large field of view was tested for on-line monitoring of coagulation and syneresis in a goat cheese (Murcia al Vino) manufactured under industrial conditions. Cheesemaking was carried out concurrently in a 12-L pilot vat and a 10,000-L industrial vat following the normal cheesemaking protocol. Cheese moisture, whey fat content, hardness, springiness, and adhesiveness were measured during syneresis. The results obtained show that cutting time is best predicted by considering the coagulation ratio at the inflection point and the percentage increase in the ratio during coagulation, with no need for the first derivative. The large field of view reflectance ratio provided good results for the prediction of moisture content, yield, hardness, springiness, and adhesiveness of the final cheese.
Collapse
Affiliation(s)
- S Rovira
- Department of Food Science and Technology, Veterinary Faculty, Regional Campus of International Excellence Campus Mare Nostrum, University of Murcia, Espinardo, E-30071, Murcia, Spain.
| | | | | | | | | | | |
Collapse
|
|
44
|
Abella M, Vaquero JJ, Sisniega A, Pascau J, Udías A, García V, Vidal I, Desco M. Software architecture for multi-bed FDK-based reconstruction in X-ray CT scanners. Comput Methods Programs Biomed 2012; 107:218-232. [PMID: 21908068 DOI: 10.1016/j.cmpb.2011.06.008] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/30/2010] [Revised: 05/13/2011] [Accepted: 06/23/2011] [Indexed: 05/31/2023]
Abstract
Most small-animal X-ray computed tomography (CT) scanners are based on cone-beam geometry with a flat-panel detector orbiting in a circular trajectory. Image reconstruction in these systems is usually performed by approximate methods based on the algorithm proposed by Feldkamp et al. (FDK). Besides the implementation of the reconstruction algorithm itself, in order to design a real system it is necessary to take into account numerous issues so as to obtain the best quality images from the acquired data. This work presents a comprehensive, novel software architecture for small-animal CT scanners based on cone-beam geometry with circular scanning trajectory. The proposed architecture covers all the steps from the system calibration to the volume reconstruction and conversion into Hounsfield units. It includes an efficient implementation of an FDK-based reconstruction algorithm that takes advantage of system symmetries and allows for parallel reconstruction using a multiprocessor computer. Strategies for calibration and artifact correction are discussed to justify the strategies adopted. New procedures for multi-bed misalignment, beam-hardening, and Housfield units calibration are proposed. Experiments with phantoms and real data showed the suitability of the proposed software architecture for an X-ray small animal CT based on cone-beam geometry.
Collapse
Affiliation(s)
- M Abella
- Unidad de Medicina Experimental, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
| | | | | | | | | | | | | | | |
Collapse
|
|
45
|
Escapa A, Gil-Carrera L, García V, Morán A. Performance of a continuous flow microbial electrolysis cell (MEC) fed with domestic wastewater. Bioresour Technol 2012; 117:55-62. [PMID: 22609714 DOI: 10.1016/j.biortech.2012.04.060] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/12/2011] [Revised: 04/17/2012] [Accepted: 04/18/2012] [Indexed: 05/05/2023]
Abstract
In this study, MEC performance was investigated in terms of chemical oxygen demand (COD) removal, hydrogen production rate and energy consumption during continuous domestic wastewater (dWW) treatment at different organic loading rates (OLR) and applied voltages (Vapp). While the COD removal efficiency was improved at low OLRs, the electrical energy required to remove 1g of COD was significantly increased with decreasing the OLR. Hydrogen production exhibited a Monod-type trend as function of the OLR reaching a maximum production rate of 0.30 L/(Lrd). Optimal Vapp was found to be highly dependent on the strength of the dWW. The results also confirmed the fact that MEC performance can be optimized by setting Vapp at the onset potential of the diffusion control region. Although low columbic efficiencies and the occurrence of hydrogen recycling limited significantly the reactor performance, these results demonstrate that MEC can be successfully used for dWW treatment.
Collapse
Affiliation(s)
- A Escapa
- Chemical and Environmental Bioprocess Engineering Group, Natural Resources Institute (IRENA), University of Leon, Avda. de Portugal 41, Leon 24009, Spain
| | | | | | | |
Collapse
|
|
46
|
Herrera A, Herrera M, Martín P, Domínguez G, Silva J, García V, García J, García de Herreros A, Bonilla F, Pena C. 181 Determination of Snail1 Paracrine Functions – Implication in Pro-tumorogenic Abilities on Colorectal Epithelial Cells Lines. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70880-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
|
47
|
Herrera M, Herrera A, Martin P, Domínguez G, Silva J, García V, García J, Bonilla F, Pena C. 143 Heterogeneity of Cancer-Associated Fibroblasts From Human Primary Colon Tumors in Their Pro-tumorogenic Abilities on Cancer Cells. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70843-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
|
48
|
Orengo J, Buendía A, Ruiz-Ibáñez M, Madrid J, Del Río L, Catalá-Gregori P, García V, Hernández F. Evaluating the efficacy of cinnamaldehyde and Echinacea purpurea plant extract in broilers against Eimeria acervulina. Vet Parasitol 2012; 185:158-63. [DOI: 10.1016/j.vetpar.2011.09.024] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2011] [Revised: 09/01/2011] [Accepted: 09/15/2011] [Indexed: 11/24/2022]
|
|
49
|
Chaparro M, Panés J, García V, Merino O, Nos P, Domènech E, Peñalva M, García-Planella E, Esteve M, Hinojosa J, Andreu M, Muñoz F, Gutiérrez A, Mendoza JL, Barrio J, Barreiro-de M, Vera I, Vilar P, Cabriada JL, Montoro MA, Aldeguer X, Saro C, Gisbert JP. Long-term durability of response to adalimumab in Crohn's disease. Inflamm Bowel Dis 2012; 18:685-90. [PMID: 21618353 DOI: 10.1002/ibd.21758] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/18/2011] [Accepted: 04/04/2011] [Indexed: 12/19/2022]
Abstract
BACKGROUND Adalimumab is an effective treatment for Crohn's disease (CD), but may also be associated with loss of response. Few reports provide insight into the durability of treatment of CD with adalimumab for periods longer than 12 months in clinical practice. AIMS To evaluate the long-term durability of adalimumab maintenance treatment and to identify predictive factors associated with loss of response. METHODS CD patients who initially responded to adalimumab were evaluated in a historical cohort study. Maintenance of long-term response was estimated using Kaplan-Meier analysis. Cox regression analysis was performed to identify potential predictive factors for loss of efficacy. RESULTS In all, 380 CD patients were included (mean age, 38 years; 52% female). Of these, 43% had ileocolic CD, 50% inflammatory CD, and 41% perianal CD. Median follow-up with adalimumab was 8 months (range, 4-75 months). The annual risk of loss of response to adalimumab was 18% per patient-year of follow-up. Twenty-eight percent of patients were anti-TNF-naïve and 72% anti-TNF-experienced. The loss of efficacy was 8% per patient-year of follow-up in the anti-TNF-naïve patients and 22% in the anti-TNF-experienced group (P < 0.01). In the multivariate analysis, the presence of extraintestinal manifestations (hazard ratio [HR] = 1.7; 95% confidence interval [CI] = 1.02-2.9) and previous experience with other anti-TNF agents (HR = 2.5,95% CI = 1.2-5.3) were associated with higher risk of loss of efficacy. CONCLUSIONS A relevant proportion of CD patients on long-term adalimumab lost response. The risk of loss of response was higher (more than 2-fold) in anti-TNF-experienced than in anti-TNF-naïve patients (22% vs. 8% per patient-year of treatment). Having extraintestinal manifestations seems to increase the risk of loss of efficacy.
Collapse
Affiliation(s)
- M Chaparro
- Gastroenterology Units of Hospital de La Princesa and Instituto de Investigación Sanitaria Princesa, IP, Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
50
|
García V, Sánchez J, Mollineda R. On the effectiveness of preprocessing methods when dealing with different levels of class imbalance. Knowl Based Syst 2012. [DOI: 10.1016/j.knosys.2011.06.013] [Citation(s) in RCA: 113] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|